Physician profile
William Gilmore
NPI 1831197136
$6,530.21
in general payments reported to CMS, 2019-2025
16 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $76.17 · 2021: $573 · 2022: $1,254 · 2023: $1,082 · 2024: $1,274 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.52 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,584.02 | 2019-2025 | |
| Janssen Biotech, INC. | $1,106.12 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $832.37 | 2019-2022 | |
| Amgen INC. | $560.07 | 2019-2024 | Otezla |
| Genzyme Corporation | $478.51 | 2019-2025 | |
| Incyte Corporation | $457.71 | 2022-2025 | Opzelura, Opzelura |
| Celgene Corporation | $246.24 | 2019 | |
| Ucb, INC. | $224.34 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $223.29 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $214.88 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $132.21 | 2021-2023 | Dupixent |
| Almirall LLC | $104.95 | 2019 | |
| Lilly USA, LLC | $104.50 | 2025 | Ebglyss |
| Pfizer INC. | $97.75 | 2024 | |
| Arcutis Biotherapeutics, INC. | $91.85 | 2025 | Zoryve |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $71.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.